The featured article strengthens the growing body of clinical evidence for Nociscan by highlighting a successful case study. The special edition on pain features breakthrough innovations that shape the future of spine care. IJSS publishes more than 150 articles annually representing more than 40 countries.
BROOMFIELD, Colo., Dec. 4, 2025 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company leveraging proprietary augmented intelligence (AI) algorithms and biomarkers to help physicians identify the location of chronic low back pain, today announced the publication of a Tech Update feature article, sponsored by Aclarion, in the Next Issue special on pain from the International Journal of Spine Surgery (IJSS).
“The IJSS special issue on pain highlights a simple truth: pain is not just a symptom, it is a complex neurobiological, psychological and existential condition,” said Morgan P. Lorio, MD, FACS, guest editor. “As more granular diagnoses and increasingly granular ICD-10 classifications emerge, including pre-MRS tools capable of identifying the pain driver, clinicians are gaining new ways of ‘seeing’ pain that were previously inaccessible. This issue brings together innovations that integrate objective biomarkers with clinical judgment, ultimately improving how we diagnose, treat, and prevent suffering. IJSS is publishing this issue now because the field is at a point of inflection and our patients deserve nothing less than a more complete, science-based understanding of pain.”
Aclarion’s Nociscan solution is the first evidence-backed SaaS platform that non-invasively helps doctors distinguish between painful and non-painful discs in the lumbar spine for the approximately 266 million people suffering from chronic low back pain worldwide.
In the case example highlighted, a 27-year-old patient with chronic low back pain initially underwent an MRI of the lumbar spine which visually suggested that the L4/5 and L5/S1 disc levels were likely the source of this patient’s pain. The treating surgeon subsequently ordered a four-level Nociscan examination to gather more information. Nociscan revealed pain biomarkers for the L5/S1 disc but not for the L4/5 disc. The surgeon used this information along with the MRI data and the patient’s overall medical history to limit the surgical intervention to an artificial disc replacement on the L5/S1 disc only, resulting in the elimination of the patient’s pain and full return to an active lifestyle.
“We are pleased to have Nociscan’s technology update appear in the special pain issue of such a high caliber magazine like IJSS,” said Ryan Bond, chief strategy officer at Aclarion. “The journal has long been a leader among its peers in advancing scientific and clinical excellence in spinal care. The special issue on pain is emblematic of its commitment to advancing the science and practice of surgical and nonoperative interventions to restore and improve spinal function. Likewise, at Aclarion, we are dedicated to providing physicians with new insights from magnetic resonance spectroscopy (MRS) to better understand a patient’s pain and differentiate between pathological pain and aging. physiological”.
IJSS is a leading peer-reviewed journal and the special issue on pain highlights innovations that are shaping the future of spine care. The IJSS is dedicated to educating spine surgeons worldwide by reporting on the scientific basis, indications, surgical techniques, complications, outcomes, and follow-up data of promising spine procedures. Additionally, the IJSS periodically publishes supplements, called special issues, such as the Pain Issue, to provide information focused on high-impact areas of clinical need and innovation.
To read the advance release online, follow this link.
To find a Nociscan center, see our site map here.
For more information about Nociscan, please email: info@aclarion.com
All organizations cited and/or quotes from individuals who are not part of Aclarion have reviewed and approved the content of this document.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages magnetic resonance spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers and augmented intelligence algorithms to optimize clinical treatments. The company is addressing the chronic low back pain market for the first time with Nociscan, the first evidence-backed SaaS platform that non-invasively helps doctors distinguish between painful and non-painful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers that have been shown to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate whether a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical information about the location of a patient’s low back pain, giving clinicians clarity to optimize treatment strategies. For more information, visit www.aclarion.com.
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding the Company’s current expectations regarding future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes,” “will,” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on management’s current plans and expectations and are subject to a number of uncertainties and risks that could materially affect the Company’s current plans and expectations, as well as the Company’s future results of operations and financial condition. Forward-looking statements in this release include, but are not limited to, statements regarding the potential benefits of our Nociscan technology and the Company’s plans for future commercialization and regulatory activities. These and other risks and uncertainties are discussed in more detail in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. The forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor contacts:
Kirin Smith
PCG Consulting, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jessica Starman
media@elev8newmedia.com
